KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.85

Dexamethasone for 12 weeks for reducing fatigue in patients receiving palliative chemotherapy: A Phase 3, Placebo-Controlled, Randomized Controlled Trial.

Venkatraman Radhakrishnan, Vidhya Gopalakrishnan, Gundrathi Vamsi Vihari, Venkata Siva Kiran Kumar Dasapathi, Jayachandran Perumal Kalaiyarasi, Surendran Veeraiah, Swaminathan Rajaraman

Support Care Cancer 33(8) 730

PMID40739403
PMCID-
DOI10.1007/s00520-025-09807-w
发表日期2025-07-31
入排依据:The trial meets criteria for oncology, human, randomized, Phase III, original result, and drug intervention, but fails the time-to-event endpoint criterion. The primary and secondary outcomes are patient-reported fatigue and quality-of-life measures (SAFE, FA-12, EORTC QLQ-C30), not time-to-event endpoints like OS, PFS, etc.
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

PURPOSE: Cancer-associated fatigue is a prevalent and distressing symptom in patients receiving palliative chemotherapy. While short-term steroid use has been employed to alleviate fatigue, its long-term efficacy and safety remain unclear. METHODS: This phase III open-label, placebo-controlled randomized trial evaluated the efficacy and safety of dexamethasone (4 mg once daily for 12 weeks) versus placebo (once daily for 12 weeks) in patients with solid malignancies undergoing palliative chemotherapy. Fatigue was assessed using the Symbolic Assessment of Fatigue Extent (SAFE) and EORTC FA-12 scales, and quality of life (QOL) was measured using the EORTC QLQ-C30 at baseline, 6 weeks, and 12 weeks. RESULTS: From October 2018 to September 2022, 126 patients were randomized; 101 were evaluable (dexamethasone: 49, placebo: 52). The median age was 46.5 years, and 67% were female. Metastatic breast cancer (28%) and lung cancer (16%) were the most common diagnoses. There were no significant differences between the arms in mean SAFE scores at 6 or 12 weeks. At 12 weeks, patients in the placebo arm reported better role functioning on the FA-12 (P = 0.02). In the EORTC QLQ-C30, the dexamethasone arm had more constipation at 6 weeks (P = 0.03) and 12 weeks (P = 0.01), and greater social sequelae at 12 weeks (P = 0.048). No significant differences in adverse events were observed between the arms. CONCLUSION: Dexamethasone did not significantly reduce cancer-associated fatigue or improve QOL in patients receiving palliative chemotherapy. The findings highlight the need to explore alternative, more effective interventions for managing fatigue in this population. TRIAL REGISTRATION: CTRI/2018/08/015222, date: 07/08/2018.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。